ERRATA

The October 20, 2010, article by Mascarenhas et al, entitled, “Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children’s Oncology Group” (J Clin Oncol 28: 4658-4663, 2010), contained errors.

In table 1, the weeks for ifosfamide and etoposide were given as 10, 19, 22, 28, 31, 37. However, the correct weeks for

ifosfamide and etoposide should have been **10, 19, 22, 31, 43**.

The online version has been corrected in departure from the print. The authors apologize for the error.

DOI: 10.1200/JCO.2015.63.3990; published July 20, 2015

The June 20, 2015, article by Mizugaki et al, entitled “Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization” (J Clin Oncol 33: 2051-2061, 2015), contained errors.

In the discussion section, third paragraph, the MTD from the phase I trial in Japan was given as 20.5% of the MTD in the United States; however, it should have been **6.8%**. Thus, the sentence should have read as follows: “In one of 54 agents, the

MTD from the phase I trial in Japan was **6.8%** of the MTD in the United States and, as a result, this agent required further investigation.”

The online version has been corrected in departure from the print. The authors apologize for the error.

DOI: 10.1200/JCO.2015.63.4790; published July 20, 2015